152 related articles for article (PubMed ID: 17689624)
21. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results.
Pickar JH; Yeh IT; Wheeler JE; Cunnane MF; Speroff L
Fertil Steril; 2003 Nov; 80(5):1234-40. PubMed ID: 14607581
[TBL] [Abstract][Full Text] [Related]
22. Addition of medroxyprogesterone acetate to conjugated equine estrogens results in insulin resistance in adipose tissue.
Shadoan MK; Kavanagh K; Zhang L; Anthony MS; Wagner JD
Metabolism; 2007 Jun; 56(6):830-7. PubMed ID: 17512317
[TBL] [Abstract][Full Text] [Related]
23. Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease.
Prentice RL; Langer RD; Stefanick ML; Howard BV; Pettinger M; Anderson GL; Barad D; Curb JD; Kotchen J; Kuller L; Limacher M; Wactawski-Wende J;
Am J Epidemiol; 2006 Apr; 163(7):589-99. PubMed ID: 16484450
[TBL] [Abstract][Full Text] [Related]
24. Conjugated estrogen plus medroxyprogesterone does not impair blood rheological properties in hypertensive postmenopausal women.
Sumino H; Ichikawa S; Takahashi T; Sakamoto H; Goto-Onozato K; Koya S; Kanda T; Nara M; Seki K; Murakami M; Kurabayashi M
Maturitas; 2006 Feb; 53(3):306-14. PubMed ID: 16040211
[TBL] [Abstract][Full Text] [Related]
25. Short-term effects of hormone therapy on serum C-reactive protein levels in postmenopausal women.
Kiran H; Kiran G
Arch Gynecol Obstet; 2006 Apr; 274(1):9-12. PubMed ID: 16369811
[TBL] [Abstract][Full Text] [Related]
26. Venous thrombosis and conjugated equine estrogen in women without a uterus.
Curb JD; Prentice RL; Bray PF; Langer RD; Van Horn L; Barnabei VM; Bloch MJ; Cyr MG; Gass M; Lepine L; Rodabough RJ; Sidney S; Uwaifo GI; Rosendaal FR
Arch Intern Med; 2006 Apr; 166(7):772-80. PubMed ID: 16606815
[TBL] [Abstract][Full Text] [Related]
27. Women's Health Initiative: not over yet. The largest study of women's health has raised at least as many questions as it has answered. Stay tuned.
Harv Womens Health Watch; 2006 May; 13(9):1-4. PubMed ID: 16696133
[No Abstract] [Full Text] [Related]
28. The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women.
Keramaris NC; Christodoulakos GE; Lambrinoudaki IV; Dalamanga A; Alexandrou AP; Bramis J; Bastounis E; Creatsas GC
Climacteric; 2007 Oct; 10(5):400-7. PubMed ID: 17852143
[TBL] [Abstract][Full Text] [Related]
29. Effects of conjugated estrogens/bazedoxifene on lipid and coagulation variables: a randomized placebo- and active-controlled trial.
Skouby SO; Pan K; Thompson JR; Komm BS; Mirkin S
Menopause; 2015 Jun; 22(6):640-9. PubMed ID: 25405570
[TBL] [Abstract][Full Text] [Related]
30. Symptom experience after discontinuing use of estrogen plus progestin.
Ockene JK; Barad DH; Cochrane BB; Larson JC; Gass M; Wassertheil-Smoller S; Manson JE; Barnabei VM; Lane DS; Brzyski RG; Rosal MC; Wylie-Rosett J; Hays J
JAMA; 2005 Jul; 294(2):183-93. PubMed ID: 16014592
[TBL] [Abstract][Full Text] [Related]
31. Sleep parameters and health-related quality of life with bazedoxifene/conjugated estrogens: a randomized trial.
Pinkerton JV; Pan K; Abraham L; Racketa J; Ryan KA; Chines AA; Mirkin S
Menopause; 2014 Mar; 21(3):252-9. PubMed ID: 23942245
[TBL] [Abstract][Full Text] [Related]
32. A randomized study of low-dose conjugated estrogens on sexual function and quality of life in postmenopausal women.
Gast MJ; Freedman MA; Vieweg AJ; De Melo NR; Girão MJ; Zinaman MJ;
Menopause; 2009; 16(2):247-56. PubMed ID: 19034054
[TBL] [Abstract][Full Text] [Related]
33. Medroxyprogesterone and conjugated oestrogen are equivalent for hot flushes: a 1-year randomized double-blind trial following premenopausal ovariectomy.
Prior JC; Nielsen JD; Hitchcock CL; Williams LA; Vigna YM; Dean CB
Clin Sci (Lond); 2007 May; 112(10):517-25. PubMed ID: 17419685
[TBL] [Abstract][Full Text] [Related]
34. Predictors of worsening insulin sensitivity in postmenopausal women.
Goodrow GJ; L'Hommedieu GD; Gannon B; Sites CK
Am J Obstet Gynecol; 2006 Feb; 194(2):355-61. PubMed ID: 16458629
[TBL] [Abstract][Full Text] [Related]
35. The Women's Health Initiative estrogen plus progestin trial: the study and how it changes our practice.
Hendrix SL
J Am Osteopath Assoc; 2003 Feb; 103(2 Suppl 2):S3-5. PubMed ID: 12625631
[No Abstract] [Full Text] [Related]
36. Estrogen replacement therapy I: a 10-year prospective study in the relationship to osteoporosis.
Nachtigall LE; Nachtigall RH; Nachtigall RD; Beckman EM
Obstet Gynecol; 1979 Mar; 53(3):277-81. PubMed ID: 218151
[TBL] [Abstract][Full Text] [Related]
37. Association of new-onset breast discomfort with an increase in mammographic density during hormone therapy.
Crandall CJ; Karlamangla A; Huang MH; Ursin G; Guan M; Greendale GA
Arch Intern Med; 2006 Aug 14-28; 166(15):1578-84. PubMed ID: 16908790
[TBL] [Abstract][Full Text] [Related]
38. Insulin resistance and body composition in Turner syndrome: Effect of sequential change in the route of estrogen administration.
Alves ST; Gallichio CT; Guimarães MM
Gynecol Endocrinol; 2006 Oct; 22(10):590-4. PubMed ID: 17135039
[TBL] [Abstract][Full Text] [Related]
39. The effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on cardiovascular metabolic risk factors.
Skouby SO; Sidelmann JJ; Nilas L; Gram J; Jespersen J
Climacteric; 2008; 11(6):489-97. PubMed ID: 18991076
[TBL] [Abstract][Full Text] [Related]
40. [Hormone replacement therapy and cognitive function].
Huang CP; Hong CT; Huang IT
Acta Neurol Taiwan; 2006 Dec; 15(4):273-7. PubMed ID: 17214093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
